• Publications
  • Influence
A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity
The MMP-9 antisense PMO inhibited in vitro prostate cancer cell proliferation, invasion and in vivo angiogenesis and establishes the feasibility of developing a site-directed, nontoxic antisense therapeutic agent for inhibiting local invasion and metastasis. Expand
Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans.
It is demonstrated that inhibition of c-Myc expression by antisense phosphorodiamidate morpholino oligomer is a promising new and safe therapeutic strategy for prostate cancer. Expand
Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics.
This review will summarize the preclinical studies with PMOs on the road to their development as therapeutic agents with particular emphasis on in vivo biodistribution and pharmacokinetics. Expand
Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism.
Studies indicate AVI-4557 is an effective and specific inhibitor of CYP3A4 expression and sequence-dependent inhibition of cyclophosphamide-related cytocidal activity in both cell types. Expand
Manipulation of metallothionein expression in the regenerating rat liver using antisense oligonucleotides.
The results of these studies suggest that MT isoforms with their high thiol contents do play an important role in cellular functions and especially during stressful states induced by a broad range of mediators generating free radicals. Expand
c-Myc antisense limits rat liver regeneration and indicates role for c-Myc in regulating cytochrome P-450 3A activity.
It is concluded that AVI-4126, antisense oligomer to c-myc, can reduce cell proliferation in the regenerating rat liver and may indirectly influence the expression of CYP3A. Expand
In vivo Bioavailability and Pharmacokinetics of a c-MYC Antisense Phosphorodiamidate Morpholino Oligomer, AVI-4126, in Solid Tumors
These studies show PMO bioavailability in tumor tissue and establish the feasibility of using PMO targeting specific genes in human cancer clinical trials. Expand
Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats.
It is concluded that oral administration of PMOs can inhibit c-myc and CYP3A2 gene expression in rat liver by an antisense-based mechanism of action and highlight the potential for development of PMO as orally administered therapeutic agents. Expand
Antisense oligonucleotides targeted to the p53 gene modulate liver regeneration in vivo.
  • V. Arora, P. Iversen
  • Biology, Medicine
  • Drug metabolism and disposition: the biological…
  • 1 February 2000
The hypothesis that antisense ODNs can inhibit the expression of p53, resulting in the loss of the G(1)-S cell cycle checkpoint and an altered pattern of liver regeneration is tested. Expand
Transdermal Use of Phosphorodiamidate Morpholino Oligomer AVI-4472 Inhibits Cytochrome P450 3A2 Activity in Male Rats
Topical application of antisense PMO in rats is a feasible delivery strategy for gene targets in liver and underlying skin and maximum inhibition was reached at a lower dose. Expand